Characterized by impaired mucus transport and subsequent enhanced colonization of
bacteria, pulmonary infection causes major morbidity and mortality in patients with cystic …

The field of inhaled antibiotics that target Pseudomonas aeruginosa infections has made
substantial contributions to the health, disease management, and life expectancies of …

Although new inhaled antibiotics have profoundly improved respiratory diseases in cystic
fibrosis (CF) patients, lung infections are still the leading cause of death. Inhaled antibiotics …

Abstract Purpose In Europe, 4 inhaled antibiotics (tobramycin, colistimethate sodium,
aztreonam, and levofloxacin) are currently approved for the treatment of chronic …

Chronic airway infection and inflammation are key events in the clinical course of cystic
fibrosis (CF). The most relevant, best investigated strain of bacteria in these circumstances is …

In cystic fibrosis, chronic airways infection caused by Pseudomonas aeruginosa can be
treated with inhaled antibiotics such as inhaled tobramycin, aztreonam or colistin. However …

Introduction: Inhaled antibiotics are probably the safest and most effective therapy for
Pseudomonas aeruginosa chronic lung infection in cystic fibrosis (CF) patients. Areas …

Inhaled antibiotics remain an important treatment option in cystic fibrosis due to chronic
airway infection as a hallmark of the disease. Although there are now multiple options for …

Abstract Background: Pseudomonas aeruginosa (Pa) is the predominant pathogen infecting
the airways of patients with cystic fibrosis (CF). Initial colonization is usually transient and …

BACKGROUND: Various inhaled antibiotics are currently used for treating chronic
Pseudomonas aeruginosa lung infection in cystic fibrosis (CF) patients, however their …